BioSpace News Archive

Settlement will end infringement cases worldwide

Zynex, Inc. announces that it will host the Company’s 2018 fourth quarter and full year investor webcast on Tuesday, February 26, 2019 at 2:15 p.m. Mountain Time

- Amends Registration Statement on Form S-4 with SEC - Remains on Track to Hold Special Meetings of Stockholders on April 12, 2019 - Updated Investor Presentation Highlights Strong Strategic and Financial Merits of Transaction

In a live interview at DeviceTalks Boston, AdvaMed president & CEO Scott Whitaker will provide a glimpse into what’s ahead for the medical device industry in 2019.

Global pharmaceutical company, Alvogen, has launched its generic equivalent to Suboxone® sublingual film in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg, and 12 mg/3mg strengths.

Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA) has completed the Pre-Approval Inspection (PAI) of the company’s cGMP Drug Substance (DS) and Drug Product (DP) manufacturing facilities for the production of TaiMed Biologics’ Trogarzo™ with no critical findings.

Shimmer, a global leader in wearable technology for research applications, today announced the launch of Verisense, its next-generation wearable sensor platform designed from the ground up to meet the needs of clinical trial sponsors, sites and participants.

The toxic heavy metal mercury can find its way into the blood of unborn babies through the placenta by “camouflaging” itself as an amino acid

Micro Interventional Devices, Inc. announced that it is has entered into a Settlement Agreement with Neovasc, Inc.